Bin Liu

Bin Liu

Auto-generated profile, based on publicly available information

Bin Liu

Central Laboratory, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, Baoding, Hebei, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YTYu Tian
Yu Tian
MZMeng Zhang
Meng Zhang
LLLixia Liu
Lixia Liu
ZWZi-Chao Wang
Zi-Chao Wang
BLBin Liu
Bin Liu
YTYanyang Tu
Yanyang Tu
Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related deaths in the world. The development and progression of HCC are closely correlated with the abnormal regulation of non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs). Important biological pathways in cancer biology, such as cell proliferation, death, and metastasis, are impacted by these ncRNAs, which modulate gene expression. The abnormal expression of non-coding RNAs in HCC raises the possibility that they could be applied as new biomarkers for diagnosis, prognosis, and treatment targets. Furthermore, by controlling the expression of cancer-related genes, miRNAs can function as either tumor suppressors or oncogenes. On the other hand, lncRNAs play a role in the advancement of cancer by interacting with other molecules within the cell, which, in turn, affects processes such as chromatin remodeling, transcription, and post-transcriptional processes. The importance of ncRNA-driven regulatory systems in HCC is being highlighted by current research, which sheds light on tumor behavior and therapy response. This research highlights the great potential of ncRNAs to improve patient outcomes in this difficult disease landscape by augmenting the present methods of HCC care through the use of precision medicine approaches.

18 January 2024 in Cell Biology International
Verified
Journal Article
Closed access
BLBin Liu
Bin Liu
XZXiang Zhang
Xiang Zhang
ZLZikai Liu
Zikai Liu
HPHaihong Pan
Haihong Pan
HYHongxu Yang
Hongxu Yang
TSTong Shen
Tong Shen

1 October 2019 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
QZQ. Zhang
Q. Zhang
YBY. Bian
Y. Bian
JHJing Hu
Jing Hu
LLLan Li
Lan Li
MYMi Yang
Mi Yang
XQX. Qian
X. Qian
There is increasing evidence that long non-coding RNAs (lncRNAs) are involved in tumor biology and development. The chromosome 8q24.21 locus is one of the most frequently amplified genomic regions in colon cancer, and many cancer-associated lncRNAs have been found in this 8q24 region. In this study, CASC21, located at 8q24.21, was selected to further experiments in colon cancer. First, we downloaded RNA-sequencing data from the Cancer Genome Atlas (TCGA) database and analyzed the lncRNA expression profile in colon cancer. Then, CASC21, a lncRNA located at 8q24.21,was selected for further experiments. We performed qRT-PCR to detect the expression of CASC21 in colon cancer tissues and cell lines. Fluorescence in situ hybridization (FISH) assay was used to analyze the location of CASC21 in cells. Loss of function assays were used to test the efficacy of CASC21 on proliferation and invasion in colon cancer. Animal experiments including tumorigenicity studies and in vivo metastasis assays were used to determine the roles of CASC21 in tumor growth and metastasis in vivo. We found that CASC21 was significantly upregulated in colon cancer tissues compared with corresponding normal tissues. Up-regulation of CASC21 was associated with the tumor -node -metastasis (TNM) stage in colon cancer. Similarly, CASC21 was upregulated in colon cancer cell lines compared with colon epithelial cell line. FISH testing showed that CASC21 mainly located in the cytoplasm rather than the nucleus. Loss of function assays revealed that CASC21 knockdown significantly inhibited cell growth by inducing cell apoptosis and cell cycle arrest. Additionally, CASC21 knockdown promoted cell metastasis by facilitating epithelial mesenchymal transformation (EMT). Moreover, CASC21 expression was significant positively associated with MYC expression in both TCGA data and our cohort. Western blot assays showed that knockdown of CASC21 markedly reduced the expression levels of WNT targets including c-myc, β-catenin and cyclinD1. Animal studies also demonstrated that CASC21 promoted tumor growth and metastasis in colon cancer. Our results provide the first evidence that CASC21 is a novel oncogenic regulator and a potential therapeutic target in colon cancer. Xiaoping Qian. Has not received any funding. All authors have declared no conflicts of interest.

11 October 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
JWJia Wei
Jia Wei
YHY. Huang
Y. Huang
NWNan Wu
Nan Wu
LYL. Yu
L. Yu
BLB. Liu
B. Liu
Background: Recent studies have suggested that KRAS plays an important role in gastric cancer. The aim of this study was to assess the prognostic effect of KRAS mutation and expression levels in gastric cancer patients and to explore its potential role in targeted therapy.